11.42
price up icon0.71%   0.08
after-market アフターアワーズ: 11.26 -0.16 -1.40%
loading
前日終値:
$11.34
開ける:
$11.6
24時間の取引高:
8.22M
Relative Volume:
1.12
時価総額:
$1.60B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-2.9844
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
-12.62%
1か月 パフォーマンス:
-0.61%
6か月 パフォーマンス:
-19.35%
1年 パフォーマンス:
-54.15%
1日の値動き範囲:
Value
$10.91
$11.68
1週間の範囲:
Value
$10.91
$13.23
52週間の値動き範囲:
Value
$7.95
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1052)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
377
Name
Twitter
@intelliatweets
Name
次回の収益日
2026-11-05
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

Compare NTLA vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NTLA icon
NTLA
Intellia Therapeutics Inc
11.42 1.60B 67.67M -412.69M -395.87M -3.8266
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-06 開始されました Barclays Underweight
2026-07-16 ダウングレード Wolfe Research Peer Perform → Underperform
2026-03-02 アップグレード William Blair Mkt Perform → Outperform
2025-11-12 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-11 ダウングレード Evercore ISI Outperform → In-line
2025-11-07 ダウングレード JP Morgan Neutral → Underweight
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Oct 16, 2026

Ex-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rock - Endpoints News

Oct 16, 2026
pulisher
Oct 14, 2026

Intellia Therapeutics names Jing Marantz as EVP and CMO - The Pharma Letter

Oct 14, 2026
pulisher
Oct 13, 2026

Intellia Therapeutics names Jing Marantz as chief medical officer - Investing.com

Oct 13, 2026
pulisher
Oct 13, 2026

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Intellia Therapeutics

Oct 13, 2026
pulisher
Oct 12, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – BX:38I - TradingView

Oct 12, 2026
pulisher
Oct 09, 2026

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 09, 2026

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Yahoo Finance

Oct 09, 2026
pulisher
Oct 06, 2026

To cover taxes, an Intellia Therapeutics (NTLA) officer sells 1,864 shares in a mandatory sale. - Stock Titan

Oct 06, 2026
pulisher
Oct 06, 2026

Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target - marketscreener.com

Oct 06, 2026
pulisher
Oct 05, 2026

Officer Eliana Clark proposes selling 57,750 Intellia Therapeutics (Nasdaq: NTLA) shares. - Stock Titan

Oct 05, 2026
pulisher
Oct 05, 2026

Intellia Therapeutics Q2 2026 Earnings Call Transcript - Benzinga

Oct 05, 2026
pulisher
Oct 02, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2026
pulisher
Oct 02, 2026

Eight new employees got Intellia stock awards, with vesting scheduled over three years. - Stock Titan

Oct 02, 2026
pulisher
Oct 02, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Oct 02, 2026
pulisher
Oct 01, 2026

Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now? - Simply Wall Street

Oct 01, 2026
pulisher
Sep 29, 2026

Tangible book value per share of Intellia Therapeutics, Inc. – HAN:38I - TradingView

Sep 29, 2026
pulisher
Sep 29, 2026

Intellia Therapeutics, Inc. (NTLA) Stock Forecasts - Yahoo Finance

Sep 29, 2026
pulisher
Sep 29, 2026

No-Moat Intellia Therapeutics Provides Pure-Play, Long-Term Exposure to Gene Editing Therapies - Morningstar

Sep 29, 2026
pulisher
Sep 29, 2026

Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity - Barchart.com

Sep 29, 2026
pulisher
Sep 27, 2026

Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA) - Seeking Alpha

Sep 27, 2026
pulisher
Sep 25, 2026

Intellia Therapeutics Stock Short Interest Rises to 41.97% - Quiver Quantitative

Sep 25, 2026
pulisher
Sep 23, 2026

Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha

Sep 23, 2026
pulisher
Sep 23, 2026

Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits

Sep 23, 2026
pulisher
Sep 22, 2026

Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy - Yahoo Finance

Sep 22, 2026
pulisher
Sep 21, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 21, 2026
pulisher
Sep 19, 2026

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances - Yahoo Finance

Sep 19, 2026
pulisher
Sep 18, 2026

Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - Yahoo Finance

Sep 18, 2026
pulisher
Sep 12, 2026

How (NTLA) Movements Inform Risk Allocation Models - Stock Traders Daily

Sep 12, 2026
pulisher
Sep 11, 2026

Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia - investing.com

Sep 11, 2026
pulisher
Sep 11, 2026

Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia By Investing.com - Investing.com Australia

Sep 11, 2026
pulisher
Sep 11, 2026

Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings - moomoo.com

Sep 11, 2026
pulisher
Sep 10, 2026

Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com

Sep 10, 2026
pulisher
Sep 10, 2026

Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance

Sep 10, 2026
pulisher
Sep 09, 2026

H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 09, 2026

Intellia’s Lonvo-z Gains FDA Priority Review for HAE - theglobeandmail.com

Sep 09, 2026
pulisher
Sep 09, 2026

Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - moomoo.com

Sep 09, 2026
pulisher
Sep 09, 2026

FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance

Sep 09, 2026
pulisher
Sep 09, 2026

NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus

Sep 09, 2026
pulisher
Sep 09, 2026

FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb

Sep 09, 2026
pulisher
Sep 09, 2026

Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative

Sep 09, 2026
pulisher
Sep 09, 2026

H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus

Sep 09, 2026
pulisher
Sep 09, 2026

H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com

Sep 09, 2026
pulisher
Sep 09, 2026

H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com South Africa

Sep 09, 2026
pulisher
Sep 09, 2026

H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com India

Sep 09, 2026
pulisher
Sep 09, 2026

NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus

Sep 09, 2026
pulisher
Sep 09, 2026

Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Nigeria

Sep 09, 2026
pulisher
Sep 09, 2026

Citizens reiterates Intellia stock rating on FDA priority review - Investing.com

Sep 09, 2026
pulisher
Sep 09, 2026

Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Australia

Sep 09, 2026
pulisher
Sep 09, 2026

Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Canada

Sep 09, 2026

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Intellia Therapeutics Inc (NTLA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
ELIANA CLARK
Officer
Oct 05 '26
Proposed Sale
12.75
57,750
736,312
0
LEONARD JOHN M
President and CEO
Aug 21 '26
Sale
13.00
2,785
36,205
1,147,064
LEONARD JOHN M
Officer
Aug 20 '26
Proposed Sale
12.95
22,675
293,641
0
LEONARD JOHN M
President and CEO
Aug 20 '26
Sale
12.60
19,890
250,614
1,149,849
Dulac Edward J III
EVP, Chief Financial Officer
Jul 22 '26
Sale
11.25
8,111
91,249
148,175
Dulac Edward J III
EVP, Chief Financial Officer
Jul 02 '26
Sale
18.00
4,677
84,186
156,286
EDWARD DULAC
Officer
Jul 02 '26
Proposed Sale
17.24
4,677
80,631
0
Dube Michael P
VP, Chief Accounting Officer
Jul 01 '26
Sale
16.78
2,641
44,316
66,886
BASTA JAMES
EVP, General Counsel
Mar 02 '26
Sale
13.78
1,211
16,688
156,794
Clark Eliana
EVP, Chief Technical Officer
Mar 02 '26
Sale
13.78
607
8,364
93,864
$24.84
price down icon 2.20%
$10.78
price down icon 5.69%
$4.45
price down icon 6.32%
$24.17
price down icon 1.79%
$12.09
price down icon 7.43%
$27.53
price up icon 0.18%
大文字化:     |  ボリューム (24 時間):